Mounjaro Approved for Heart Attack, Stroke Risk Reduction in Diabetes

The FDA has approved Eli Lilly's Mounjaro for reducing the risk of cardiovascular death, heart attack, and stroke in adults with type 2 diabetes at high cardiovascular risk, expanding its use beyond diabetes to major cardiovascular disease prevention. This follows similar FDA approvals for Novo Nordisk's GLP-1 treatments, intensifying competition and influencing insurance coverage dynamics in the obesity and diabetes therapy markets.

This Wire brief sits within Fusion42's coverage of Health, and 13 sources have reported it between 28 Aug 2026 and 30 Aug 2026.